SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of April, 2007
SkyePharma PLC
SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.
Form 20-F X Form 40-F
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes No X
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______
3 April 2007
SkyePharma PLC ("the Company")
Notification of Major Interest in Shares
In accordance with the Disclosure and Transparency Rules 5.1.2, we have received
a notification dated 2 April 2007 from UBS Investment Bank ("UBS") stating that
as at 29 March 2007, it held a notifiable interest of 39,424,935 shares in
SkyePharma PLC, (39,424,345 shares held in the name of UBS AG London branch and
590 shares held in the name of UBS Securities LLC) which represents 4.83% of the
voting rights in the Company.
Prior to the triggering transaction, UBS held 41,701,216 Ordinary Shares and the
threshold that has been crossed is 5%.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ John Murphy
Name: John Murphy
Title:
Company Secretary
Date: April 03, 2007